Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients

Current Medical Research and Opinion

Volumn 27, Issue 11, 2011, Pages 2223-2228

  Siergiejko, Zenon ^a   Świebocka, Ewa ^a   Smith, Nicola ^b   Peckitt, Clare ^b   Leo, Jo ^b   Peachey, Guy ^b   Maykut, Robert ^c  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Allergic asthma; Immunoglobulin E; Omalizumab; Oral corticosteroid

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; IMMUNOGLOBULIN E; OMALIZUMAB;

ADD ON THERAPY; ADOLESCENT; AGED; ALLERGIC ASTHMA; ARTHRALGIA; ARTICLE; CONTROLLED CLINICAL TRIAL; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG EFFICACY; DRUG USE; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; PREDICTOR VARIABLE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; CHILD; FEMALE; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80054703208     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.620950     Document Type: Article

References (24)

1. Global Initiative for Asthma. Global strategy for asthma management and prevention. Issued January 1995 (NIH Publication No. 02-3659); updated 2002, 2003, 2004, 2005, 2006, 2007, 2008. Available at: www.ginasthma.org [Last accessed 11 February 2011]
2. Manson SC, Brown RE, Cerulli A, et al. The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. Respir Med 2009;103:975-94
3. Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005; 60:302-8 (Pubitemid 40293345)
4. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60:309-16 (Pubitemid 40293346)
5. Corren J, Casale TB, Lanier B, et al. Safety and tolerability of omalizumab. Clin Exp Allergy 2009;39:788-97
6. European Medicines Agency: Omalizumab (Xolair) full prescribing information (EU), August 2009. Available at: http://www.ema.europa.eu/ema/index. jsp? curl1/4pages/medicines/human/medicines/000606/human-med-001162. jsp&murl1/4menus/medicines/medicines.jsp&mid1/4WC0b01ac058001d125 [Last accessed 11 February 2011]
7. Genentech Inc.: Omalizumab (Xolair) full prescribing information (US), July 2008. Available at: http://www.gene.com/gene/products/information/ immunological/xolair/insert.jsp [Last accessed 11 February 2011]
8. Bousquet J, Siergiejko Z, Swiebocka E, et al. Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. Allergy 2011;66:671-8
9. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108:184-90 (Pubitemid 32735398)
10. Holgate ST, Chuchalin AG, Hébert J, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004;34:632-8 (Pubitemid 38534897)
11. Hanania NA, Alpan O, Hamilos DL, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med 2011;154:573-82
12. Busse WW, Morgan WJ, Gergen PJ, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 2011;364: 1005-15
13. Molimard M, de Blay F, Didier A, et al. Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France. Respir Med 2008;102:71-6 (Pubitemid 350161845)
14. Molimard M, Buhl R, Niven R, et al. Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: real-life data. Respir Med 2010;104:1381-5
15. Bousquet J, Rabe K, Humbert M, et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med 2007; 101:1483-92 (Pubitemid 46850589)
16. Calverley PM, Rennard SI. What have we learned from large drug treatment trials in COPD? Lancet 2007;370:774-85 (Pubitemid 47320801)
17. Cazzola M, Camiciottoli G, Bonavia M, et al. Italian real-life experience of omalizumab. Respir Med 2010;104:1410-16
18. Ducharme F, Schwartz Z, Hicks G, et al. Addition of anti-leukotriene agents to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev 2004;(2):CD003133
19. Davies H, Olson L, Gibson P. Methotrexate as a steroid sparing agent for asthma in adults. Cochrane Database Syst Rev 2000;(2):CD000391
20. Evans DJ, Cullinan P, Geddes DM. Cyclosporin as an oral corticosteroid sparing agent in stable asthma. Cochrane Database Syst Rev 2001;(2):CD002993
21. Dean T, Dewey A, Bara A, et al. Azathioprine as an oral corticosteroid sparing agent for asthma. Cochrane Database Syst Rev 2004;(1):CD003270
22. Karpel JM,Massanari, M, Geba, GB. Effectiveness of omalizumab in reducing corticosteroid burden in patients with moderate to severe persistent allergic asthma. Ann Allergy Asthma Immunol 2010;105:465-70
23. Costello RW, Long DA, Gaine S, et al. Therapy with omalizumab for patients with severe allergic asthma improves asthma control and reduces overall healthcare costs. Ir J Med Sci 2011;180(3):637-41
24. Domingo C, Moeno A, Jose Amengual M, et al. Omalizumab in the management of oral corticosteroid-dependent IGE-mediated asthma patients. Curr Med Res Opin 2011;27:45-53